Dr. Tarantino on the Importance of the DESTINY-Breast04 Trial in HER2-Low Breast Cancer

Paolo Tarantino, MD, clinical research fellow, Dana-Farber Cancer Institute, discusses the importance of the phase 3 DESTINY-Breast04 trial (NCT03734029) in HER2-low breast cancer.

The randomized, 2-arm, open-label, multicenter study compared fam-trastuzumab deruxtecan-nxki (Enhertu) to the physician’s choice standard of care in previously treated patients with HER2-low breast cancer.

DESTINY-Breast04 was the first phase 3 trial launched with the goals of confirming the paradigm of HER2-low disease, Tarantino says. The trial included patients with pretreated HER2-low tumors, including those with hormone receptor–positive and triple-negative breast cancer, Tarantino explains. To be randomized to receive trastuzumab deruxtecan or a standard-of-care chemotherapy, patients were required to have undergone at least 1 prior line of chemotherapy, Tarantino says.

Data from the trial showed trastuzumab deruxtecan elicited an improvement in progression-free survival and overall survival, compared with chemotherapy, Tarantino continues. More data from the pivotal trial are expected soon, and these findings could be practice changing in terms of how therapeutic decisions for this pretreated patient population is approached, Tarantino concludes.

Sponsored in part by Daiichi Sankyo. Content independently developed by OncLive^®